Evidence map›Paper›PMID 41220351›Full record

ArticleThe Canadian journal of urology2025

Association of urinary tract infection and low albumin/globulin ratio with chemoresistance to gemcitabine-cisplatin in advanced urothelial carcinoma.

Jingcheng Lyu, Ruiyu Yue, Yichen Zhu, Ye Tian, Xinyi Hu

Abstract read
PubMed Publisher
In one paragraph

Article in The Canadian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingcheng Lyu *Department of Urology, Capital Medical University, Beijing Friendship Hospital, Beijing, 100050, China.
Ruiyu Yue *Department of Urology, Capital Medical University, Beijing Friendship Hospital, Beijing, 100050, China.
Yichen ZhuDepartment of Urology, Capital Medical University, Beijing Friendship Hospital, Beijing, 100050, China.
Ye TianDepartment of Urology, Capital Medical University, Beijing Friendship Hospital, Beijing, 100050, China.
Xinyi HuDepartment of Urology, Capital Medical University, Beijing Friendship Hospital, Beijing, 100050, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUrothelial carcinoma (UC) remains a prevalent malignancy with high recurrence and chemoresistance rates despite gemcitabine-cisplatin (GC) chemotherapy. The study aimed to identify clinical risk factors for chemoresistance in advanced UC patients and develop a predictive model.

methodA retrospective analysis was conducted on 375 UC patients who received postoperative GC chemotherapy between 2013 and 2024. Patients were categorized into chemotherapy-resistant (CR, n = 91) and non-chemotherapy resistant (NCR, n = 284) groups based on tumor progression. Clinical, pathological, and laboratory variables were compared using t-tests and chi-square tests. Kaplan-Meier assessed overall survival (OS), and binary logistic regression identified independent predictors of chemoresistance.

resultOverall survival (OS) was significantly lower in the CR group than in the NCR group urinary tract infection (OR: 54.60; 95% CI: [21.19, 140.67]) and low A/G (OR: 0.18;95% CI: [0.03, 0.94]). The prediction model was: Logit(P)=-3.69+0.96×multifocal tumor+1.05×Tstage+4.00×long-termurinary tract infection(UTI)-1.73×A/G.

conclusionMultifocality, high T stage, persistent UTI, and low A/G ratio are significantly associated with chemoresistance to GC in UC. These routine clinical indicators may support early identification of high-risk patients and guide treatment decisions.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellDeoxycytidineDrug Resistance, NeoplasmSerum AlbuminUrinary Bladder NeoplasmsUrinary Tract InfectionsUrologic NeoplasmsAgedCisplatinFemaleGemcitabineHumansMaleMiddle AgedRetrospective StudiesCisplatinDeoxycytidineGemcitabineSerum Albuminalbumin/globulin ratiochemotherapy resistanceurinary tract infectionurothelial carcinoma

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.